Henlius will hold on to commercial rights within mainland China, Hong Kong, Macau and Taiwan, while Sandoz takes charge everywhere else globally
The company expects the US Food and Drug Administration could approve dersimelagon for EPP and XLP as early as 2027, subject to regulatory review
The fund will be managed by Aditya Khemani, Head of Equity & Fund Manager, Invesco Mutual Fund, and will be benchmarked against the BSE Healthcare TRI
All equity shares of Inzpera held by Cipla will simply stand cancelled upon the scheme taking effect, with no allotment of Cipla shares to any external shareholders
Operating revenue for the quarter grew a modest 3.93% year-on-year to Rs. 193.81 crore
Following the creation of the revised security, the pledge on the 28,280 BSVL shares, which had been maintained in favour of the debenture trustee on behalf of NCD holders, was released on August 17, 2026
Following the acquisition, Hearzap’s network will expand to 420 centres across India, supported by more than 1,000 service providers
The regulatory milestone strengthens the company’s bid to develop ACI-7104 as a potential treatment for Parkinson’s
The ruling removes a long-standing legal uncertainty surrounding the Lipitor antitrust matter and marks an important development for Sun Pharma in the US litigation
The USFDA conducted an inspection of the Raleigh facility from March 24 to April 10, 2025, following which the regulator issued a Form 483 containing 11 observations
The deal consists of cash and a $50 million seller note
More than 800 exhibitors are expected to participate, showcasing technologies and solutions spanning pharmaceutical ingredients, biotechnology, AI and contract services, finished dosage forms and more
The Danish biotech said it will move petrelintide into registrational Phase 3 trials in the second half of 2026 after Phase 2 results showed double-digit weight loss and a tolerability profile largely comparable to placebo
The initiative tackled everyday health concerns through interactive activities rather than conventional classroom lessons
API manufacturer's revenue climbs to Rs. 189.75 crore as Asia overtakes Europe as top market, while company advances new launches in ADHD and anaesthetic segments
Consolidated revenue drops to Rs. 7,944 million against a high base in Q1 FY26, even as EBITDA margin recovers sequentially
Total revenue from operations for the quarter stood at Rs. 37,402 million, up 10.9% year-over-year
Moody’s Ratings upgraded Teva’s corporate credit rating to Baa3 from Ba1
Adjusted EBITDA climbs 30.7% to Rs. 65.1 crore as treatments cross 10.3 lakh; network expands to 550 clinics across five countries
Revenue from operations rises to Rs. 39.92 crore as company reports Rs. 20.78 crore quarterly loss amid higher research and development expenses
Subscribe To Our Newsletter & Stay Updated
